Latest News

We present the strategy of a comprehensive cancer center organized to make operations pandemic proof and achieve continuity of cancer care during the COVID-19 pandemic. Disease Outbreak Response (DORS) measures implemented at our center and its satellite clinics included strict infection prevention, manpower preservation, prudent resource allocation, and adaptation of standard-of-care treatments.

To compare the image quality of the reduced field-of-view (rFOV) diffusion-weighted imaging (DWI) with the full field-of-view (fFOV) DWI in the assessment of bladder cancer (BC); and to explore the possible superiority of bi-planar (axial and sagittal) rFOV DWI over single planar fFOV DWI in predicting muscle-invasiveness of BC.

Neoadjuvant chemotherapy (NAC) is the standard of care for eligible patients with cT2-4a N0 M0 bladder cancer undergoing surgical resection. The extent to which (and if) NAC increases patient survival is not clear as clinical trials and meta-analyses have generated both negative and "borderline" positive results.

To explore the overall trends of incidence rate (IR), mortality and survival outcomes of patients with urothelial bladder cancer (UBC) over the past two decades. Patients diagnosed with UBC from 1993 to 2012 were extracted from the Surveillance, Epidemiology and End Result (SEER) 18 database.

We aimed to test the hypothesis that the immune-modulatory effect of statins may improve survival outcomes in patients with non-muscle invasive bladder cancer (NMIBC). We focused on a cohort of patients diagnosed with high risk NMIBC, that were treated with intravesical BCG immunotherapy.

Radical nephroureterectomy (RNU) with the concomitant excision of the distal ureter and bladder cuff is the current standard of care for the treatment of muscle invasive and/or high-risk upper tract urothelial carcinoma (UTUC).

Ashish Kamat: Welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from MD Anderson Cancer Center in Houston. And it’s my pleasure to welcome today, Andrew Lenis, who’s a Fellow in Urologic Oncology at the other cancer center in New York, Memorial Sloan Kettering Cancer Center. And he’s going to present to us […]

Rhabdomyosarcoma (RMS) is a soft tissue tumor that commonly occurs in childhood and adolescence. It is less prevalent in adulthood, accounting for 2%–5% of adult soft tissue tumors. RMS has a higher propensity to occur in genitourinary organs in adults than in pediatric patients. The clinical outcomes of adult patients with kidney, bladder, and prostate […]

Considering the aggressive variability of prostate cancer (PCa) and the wide range of available treatments, European guidelines recommend different treatment options according to prognostic risk stratification.1 However, to date there’s no consensus about which is the best timeframe for such tumour to provide treatment and if different risk classes might have reserved different timing for […]

Every prostate cancer (PCa) patient should receive the right treatment at the right time. In order to map the variance between different European countries in their political and clinical approaches to treating PCa, the Let’s Talk Prostate Cancer (LTPC) Digital Atlas was launched at www.letstalkprostatecancer.com. The Atlas provides an overview of PCa outcomes in the […]